- Home
- MGRX vs PMN Comparison
MGRX vs PMN Comparison
Compare MGRX & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- PMN
- Stock Information
- Founded
- MGRX 2021
- PMN 2004
- Country
- MGRX United States
- PMN Canada
- Employees
- MGRX N/A
- PMN N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- PMN Pharmaceuticals and Biotechnology
- Sector
- MGRX Technology
- PMN Health Care
- Exchange
- MGRX Nasdaq
- PMN Nasdaq
- Market Cap
- MGRX 18.6M
- PMN 16.0M
- IPO Year
- MGRX 2023
- PMN N/A
- Fundamental
- Price
- MGRX $1.71
- PMN $0.77
- Analyst Decision
- MGRX
- PMN Strong Buy
- Analyst Count
- MGRX 0
- PMN 3
- Target Price
- MGRX N/A
- PMN $4.33
- AVG Volume (30 Days)
- MGRX 145.9K
- PMN 21.3M
- Earning Date
- MGRX 08-13-2025
- PMN 08-11-2025
- Dividend Yield
- MGRX N/A
- PMN N/A
- EPS Growth
- MGRX N/A
- PMN N/A
- EPS
- MGRX N/A
- PMN N/A
- Revenue
- MGRX $511,084.00
- PMN N/A
- Revenue This Year
- MGRX N/A
- PMN N/A
- Revenue Next Year
- MGRX N/A
- PMN N/A
- P/E Ratio
- MGRX N/A
- PMN N/A
- Revenue Growth
- MGRX N/A
- PMN N/A
- 52 Week Low
- MGRX $1.32
- PMN $0.38
- 52 Week High
- MGRX $7.66
- PMN $1.59
- Technical
- Relative Strength Index (RSI)
- MGRX 51.65
- PMN 54.99
- Support Level
- MGRX $1.61
- PMN $0.77
- Resistance Level
- MGRX $1.77
- PMN $1.06
- Average True Range (ATR)
- MGRX 0.14
- PMN 0.16
- MACD
- MGRX 0.02
- PMN 0.01
- Stochastic Oscillator
- MGRX 43.68
- PMN 30.80
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.